2/5
02:57 pm
vrdn
Hot Picks: Biotech rebound turns to rare disease catalysts [BNN Bloomberg (Canada)]
Low
Report
Hot Picks: Biotech rebound turns to rare disease catalysts [BNN Bloomberg (Canada)]
2/4
08:03 am
vrdn
Viridian Therapeutics (NASDAQ:VRDN) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $42.00 price target on the stock.
Medium
Report
Viridian Therapeutics (NASDAQ:VRDN) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $42.00 price target on the stock.
2/3
08:50 am
vrdn
Viridian Therapeutics (NASDAQ:VRDN) had its price target raised by analysts at Wells Fargo & Company from $26.00 to $29.00. They now have an "equal weight" rating on the stock.
Low
Report
Viridian Therapeutics (NASDAQ:VRDN) had its price target raised by analysts at Wells Fargo & Company from $26.00 to $29.00. They now have an "equal weight" rating on the stock.
1/26
02:08 pm
vrdn
Viridian Therapeutics: Cautious Optimism As Key Milestones Approach (Rating Downgrade) [Seeking Alpha]
Low
Report
Viridian Therapeutics: Cautious Optimism As Key Milestones Approach (Rating Downgrade) [Seeking Alpha]
1/23
05:09 am
vrdn
Viridian Therapeutics (NASDAQ:VRDN) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Viridian Therapeutics (NASDAQ:VRDN) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
1/20
10:06 am
vrdn
Viridian Therapeutics (NASDAQ:VRDN) had its "outperform" rating reaffirmed by analysts at Evercore ISI.
Low
Report
Viridian Therapeutics (NASDAQ:VRDN) had its "outperform" rating reaffirmed by analysts at Evercore ISI.
1/9
06:10 am
vrdn
Viridian Therapeutics (NASDAQ:VRDN) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.
Medium
Report
Viridian Therapeutics (NASDAQ:VRDN) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.
1/8
04:01 pm
vrdn
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1/8
12:49 pm
vrdn
Viridian Therapeutics (NASDAQ:VRDN) had its price target lowered by analysts at Truist Financial Corporation from $41.00 to $40.00. They now have a "buy" rating on the stock.
Low
Report
Viridian Therapeutics (NASDAQ:VRDN) had its price target lowered by analysts at Truist Financial Corporation from $41.00 to $40.00. They now have a "buy" rating on the stock.
1/7
10:02 am
vrdn
Viridian Therapeutics (NASDAQ:VRDN) is now covered by analysts at UBS Group AG. They set a "buy" rating on the stock.
Low
Report
Viridian Therapeutics (NASDAQ:VRDN) is now covered by analysts at UBS Group AG. They set a "buy" rating on the stock.
1/6
07:22 am
vrdn
Viridian Therapeutics Prepares for Transformational 2026 [Yahoo! Finance]
Low
Report
Viridian Therapeutics Prepares for Transformational 2026 [Yahoo! Finance]
1/6
07:01 am
vrdn
Viridian Therapeutics Prepares for Transformational 2026
Low
Report
Viridian Therapeutics Prepares for Transformational 2026
12/23
08:02 am
vrdn
Viridian Therapeutics (NASDAQ:VRDN) had its price target raised by analysts at Needham & Company LLC from $34.00 to $42.00. They now have a "buy" rating on the stock.
Low
Report
Viridian Therapeutics (NASDAQ:VRDN) had its price target raised by analysts at Needham & Company LLC from $34.00 to $42.00. They now have a "buy" rating on the stock.
12/22
07:15 am
vrdn
Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease [Yahoo! Finance]
Low
Report
Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease [Yahoo! Finance]
12/22
07:00 am
vrdn
Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease
Low
Report
Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease
12/10
08:36 am
vrdn
Viridian Therapeutics (NASDAQ:VRDN) had its price target raised by analysts at Wedbush from $42.00 to $47.00. They now have an "outperform" rating on the stock.
Low
Report
Viridian Therapeutics (NASDAQ:VRDN) had its price target raised by analysts at Wedbush from $42.00 to $47.00. They now have an "outperform" rating on the stock.
12/5
07:00 am
vrdn
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/3
08:43 am
vrdn
Viridian Therapeutics (NASDAQ:VRDN) was given a new $47.00 price target on by analysts at William Blair.
Low
Report
Viridian Therapeutics (NASDAQ:VRDN) was given a new $47.00 price target on by analysts at William Blair.
12/3
07:19 am
vrdn
Viridian Therapeutics (NASDAQ:VRDN) is now covered by analysts at William Blair. They set an "outperform" rating on the stock.
Low
Report
Viridian Therapeutics (NASDAQ:VRDN) is now covered by analysts at William Blair. They set an "outperform" rating on the stock.
11/24
09:04 am
vrdn
Viridian Therapeutics (NASDAQ:VRDN) was given a new $41.00 price target on by analysts at Truist Financial Corporation.
Medium
Report
Viridian Therapeutics (NASDAQ:VRDN) was given a new $41.00 price target on by analysts at Truist Financial Corporation.
11/24
08:43 am
vrdn
Viridian Therapeutics (NASDAQ:VRDN) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.
Medium
Report
Viridian Therapeutics (NASDAQ:VRDN) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.
11/16
10:26 pm
vrdn
RBC Capital Remains Bullish on Viridian Therapeutics (VRDN) Following Q3 2025 Results [Yahoo! Finance]
Low
Report
RBC Capital Remains Bullish on Viridian Therapeutics (VRDN) Following Q3 2025 Results [Yahoo! Finance]